ProAct Chief Operating Offier Deborah Dempsey says plan sponsors still lack the data and visibility to know whether they were shorted on a 340B claim.
News|Articles|September 29, 2023
The Durability of Roctavian and the Need for Corticosteroids
Author(s)Peter Wehrwein, Managing Editor
Data from clinical trials suggest that the vast majority of the patients respond to the gene therapy for hemophilia A, says Courtney Thornburg, M.D., M.S. But there is also decreasing factor expression.
Advertisement
Second of four parts
In this segment of a video interview with Managed Healthcare Executive, Courtney Thornburg, M.D., M.S., discusses the durability of Roctavian (valoctocogene roxaparvovec) in producing factor VIII and liver inflammation that is treated with corticosteroids.
Thornburg, the medical director of the Hemophilia and Thrombosis Treatment Center at Rady Children’s Hospital-San Diego, was the lead author of a review article about hemophilia gene therapy that was published in July in the journal BioDrugs.
Advertisement
Related to this article
AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.
OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point drop in body mass index and improved mental health.
Yellow eyelid Xanthelasma signals hidden high cholesterol and cardiovascular disease risk, tripling heart attack and stroke odds; Negin Yavari, M.D., and her team urge screening.
Maladaptive coping at baseline raised relapse and symptom risk over 12 months in first episode psychosis, King's College London researchers found.
Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.
ProAct's Deborah Dempsey, Pharm.D., MBA, RPh, explains how 340B discounts to healthcare entities are in conflict with rebates that manufacturers pay to health plan sponsors.
Optum Rx's Anne Mall, M.H.A., says her company's AI is surfacing clinical details buried in providers' chart notes so clinicians can decide on therapy faster.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Navitus launches GLP-1 drug management programs
2
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
3
Deborah Dempsey, Pharm.D., MBA, RPh, on 340B discounts vs. rebates | PBMI 2026
4
Judi Health, Employers Health team up to launch new PBM solution
5